BioNexus Gene Lab (BGLC) Financial Statements & Analysis

BioNexus Gene Lab (BGLC) Income Statement

BioNexus Gene Lab reported revenue of $7.42M in fiscal 2026 (fiscal year ended Dec 31, 2025). BioNexus Gene Lab posted a net loss of $2.98M. Gross margin was 14.6% and operating margin -42.5%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $76.16K, down 96.6% from the same quarter a year earlier.

BioNexus Gene Lab Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

BioNexus Gene Lab Corp. income statement - Annual data in millions USD
Breakdown	FY 2026	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	7.42	9.51	9.77	10.93	13.36	11.39	0.13	0.21	0.11
Cost of Revenue	6.34	8.22	8.44	9.67	11.10	9.67	0.07	0.18	0.03
Gross Profit	1.09	1.29	1.33	1.26	2.27	1.72	0.06	0.03	0.08
Operating Expenses
Research & Development	0.05	0.05	0.05	0.00	0.00	0.00	0.00	0.00	0.00
Selling, General & Administrative	4.07	4.00	3.04	1.73	1.28	1.33	0.36	0.24	0.21
Operating Expenses	4.24	3.25	3.92	1.55	1.21	0.45	0.33	-0.03	0.21
Operating Income	-3.16	-1.96	-2.59	-0.29	1.06	1.27	-0.28	0.06	-0.13
Other Income/Expense
Interest Income	0.08	0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.02	0.02	0.01	0.01	-0.01	0.01	0.00	0.00	0.00
Other Income/Expense	0.11	0.24	-0.01	0.17	-0.01	-0.01	0.00	0.00	0.00
Income
Income Before Tax	-2.98	-1.59	-2.61	-0.30	1.04	1.26	-0.28	0.06	-0.12
Income Tax Expense	0.00	0.00	0.02	0.05	0.29	0.17	-0.03	0.03	0.00
Net Income	-2.98	-1.60	-2.63	-0.36	0.75	1.09	-0.25	0.03	-0.12
Net Income - Continuous Operations	-2.98	-1.60	-2.63	-0.36	0.75	1.09	-0.25	0.03	-0.12
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	-2.80	-1.42	-2.49	-0.19	1.15	1.38	-0.22	0.10	-0.10
EBIT	-2.97	-1.57	-2.59	-0.29	1.06	0.57	-	-	-
Depreciation & Amortization	0.17	0.15	0.11	0.11	0.09	0.10	0.05	0.04	0.02
Earnings Per Share
Basic EPS	-2.00	-1.00	-2.00	-	1.00	1.00	-	-	-
Diluted EPS	-2.00	-1.00	-2.00	-	1.00	1.00	-	-	-
Basic Shares Outstanding	1.86	1.78	1.72	1.44	1.43	0.86	0.72	0.55	0.62
Diluted Shares Outstanding	1.86	1.78	1.72	1.44	1.43	0.86	0.72	0.55	0.62

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About BioNexus Gene Lab Financial Statements

What was BioNexus Gene Lab's revenue in fiscal 2026?

BioNexus Gene Lab reported revenue of $7.42M in fiscal 2026 (fiscal year ended Dec 31, 2025).

Is BioNexus Gene Lab profitable?

No. BioNexus Gene Lab reported a net loss of $2.98M in fiscal 2026.

What is BioNexus Gene Lab's operating margin?

BioNexus Gene Lab's operating income was −$3.16M on revenue of $7.42M in fiscal 2026, an operating margin of -42.5%.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition